CompletedNCT01627782
Ketamine for treatment-resistant depression
Medication studyAges 18–64United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 6, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 68
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT01627782
- Official title
Show the full official title
A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
Get this study by email
Recruitment & locations
CompletedBirmingham · Little Rock · Centennial
10 more locations
- Hartford
- New Haven
- Atlanta
- Rockville
- Marlton
- New York
- Allentown
- Charleston
- Dallas
- Salt Lake City
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Placebo and ketamine.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
